Loading clinical trials...

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT01283542

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.

Lead sponsor: Novartis Pharmaceuticals•7 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

COMPLETEDNA

Implementing eHealth Interventions Into Regular Clinical Practice

NCT04218721 · Renal Transplant Recipients, Non-functioning Pituitary Adenoma

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 26, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment20

Start dateNov 2012

Last updatedApr 26, 2019

Condition

Non-functioning Pituitary Adenoma

Locations shown

Novartis Investigative Site

Fortaleza, Ceará

Novartis Investigative Site

Curitiba, Paraná

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 26, 2019Data synced to Clareo: May 16, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Implementing eHealth Interventions Into Regular Clinical Practice

Trial snapshot

Condition

Locations shown

For caregivers